XKRX206640
Market cap230mUSD
Dec 27, Last price
15,440.00KRW
1D
-2.40%
1Q
-9.65%
Jan 2017
-17.75%
IPO
-22.80%
Name
Boditech Med Inc
Chart & Performance
P/E
13.07
P/S
2.53
EPS
1,181.12
Div Yield, %
0.97%
Shrs. gr., 5y
-0.96%
Rev. gr., 5y
15.18%
Revenues
134.22b
+13.67%
Net income
25.95b
+7.43%
CFO
34.30b
+48.69%
Dividend
Mar 29, 2024200 KRW/sh
Profile
Boditech Med Inc. develops products for in-vitro diagnostics and diagnostic reagents. It offers ichroma II, an automatic or semiautomatic in-vitro diagnostic device that measures the concentration of analytes, contained in blood, urine, or other samples, in quantitative, or semi-quantitative ways; automated fluorescent immunoassay systems under AFIAS-6 and AFIAS-1 names that uses blood, urine, and other samples to measure quantitatively or semi-quantitatively the concentration of targeted analytes; ichroma-50, an automatic immunoassay analyzer that measures the concentration of targeted analytes in body fluids, such as blood, urine, and other samples; and ichroma M2, a portable analyzer intended to be used with in vitro diagnostic immunofluorescent assay kits for screening, monitoring and/or examining routine physics in centralized laboratories of hospitals or physician's clinics. The company also provides Ichroma TRIAS Reader, an in vitro diagnostic device that measures the concentration of targeted analyte from various samples, such as blood, nasal swabs, and nasopharyngeal swabs; Hemochroma PLUS, an in vitro diagnostic device to quantitative test total hemoglobin concentration in the blood; i-chamber, an auxiliary device for the ichroma systems; and HandyRay, a laser device for the capillary blood sampling without a needle. Its solutions cover areas, such as cardiac, cancer, diabetes, hormone, infection, infectious disease, gastrointestinal, rheumatoid arthritis, and others. The company offers its products through a network of approximately 100 sales agencies worldwide. Boditech Med Inc. was founded in 1998 and is headquartered in Chuncheon, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 134,219,240 13.67% | 118,076,843 -25.13% | 157,707,960 9.42% | ||||||
Cost of revenue | 80,782,350 | 77,597,438 | 86,436,220 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 53,436,889 | 40,479,404 | 71,271,740 | ||||||
NOPBT Margin | 39.81% | 34.28% | 45.19% | ||||||
Operating Taxes | 4,898,834 | 1,683,777 | 8,644,405 | ||||||
Tax Rate | 9.17% | 4.16% | 12.13% | ||||||
NOPAT | 48,538,055 | 38,795,627 | 62,627,335 | ||||||
Net income | 25,946,636 7.43% | 24,151,534 -45.56% | 44,366,589 -2.47% | ||||||
Dividends | (3,295,169) | (4,269,927) | (4,608,504) | ||||||
Dividend yield | 0.73% | 1.86% | 1.20% | ||||||
Proceeds from repurchase of equity | 12,300 | (7,077,621) | (8,725,479) | ||||||
BB yield | 0.00% | 3.09% | 2.27% | ||||||
| Debt | |||||||||
Debt current | 7,917,421 | 5,725,203 | 4,400,267 | ||||||
Long-term debt | 3,859,378 | 3,170,044 | 2,465,452 | ||||||
Deferred revenue | 870,044 | 865,452 | |||||||
Other long-term liabilities | 47,904 | 480,856 | 378,673 | ||||||
Net debt | (86,271,851) | (63,222,028) | (71,121,887) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 34,299,696 | 23,068,408 | 49,927,140 | ||||||
CAPEX | (5,630,193) | (16,905,123) | (18,411,366) | ||||||
Cash from investing activities | (16,122,485) | (24,454,171) | (15,972,157) | ||||||
Cash from financing activities | (1,937,701) | (10,161,601) | (19,567,351) | ||||||
FCF | 49,227,325 | 19,446,745 | 45,591,948 | ||||||
| Balance | |||||||||
Cash | 76,197,828 | 60,459,055 | 68,468,716 | ||||||
Long term investments | 21,850,823 | 11,658,220 | 9,518,891 | ||||||
Excess cash | 91,337,689 | 66,213,433 | 70,102,209 | ||||||
Stockholders' equity | 197,539,587 | 176,740,639 | 156,110,479 | ||||||
Invested Capital | 116,694,541 | 117,222,285 | 91,250,110 | ||||||
ROIC | 41.50% | 37.22% | 77.96% | ||||||
ROCE | 25.62% | 21.94% | 43.89% | ||||||
| EV | |||||||||
Common stock shares outstanding | 21,968 | 22,364 | 22,917 | ||||||
Price | 20,500.00 100.00% | 10,250.00 -38.99% | 16,800.00 -29.11% | ||||||
Market cap | 450,346,501 96.46% | 229,229,719 -40.46% | 385,006,810 -29.45% | ||||||
EV | 375,292,959 | 177,283,430 | 324,029,717 | ||||||
EBITDA | 61,668,408 | 47,951,906 | 77,312,351 | ||||||
EV/EBITDA | 6.09 | 3.70 | 4.19 | ||||||
Interest | 350,388 | 203,924 | 196,504 | ||||||
Interest/NOPBT | 0.66% | 0.50% | 0.28% | ||||||